How does EBOS.F's PE Ratio compare to its peers?

EBOS.F is expensive based on its Price-To-Earnings Ratio (24.6x) compared to the peer average (24x).

How does EBOS.F's PE Ratio compare vs other companies in the US Healthcare Industry?

EBOS.F is expensive based on its Price-To-Earnings Ratio (24.6x) compared to the US Healthcare industry average (21.9x).

What is EBOS.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate EBOS.F's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of EBOS.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

EBOS.F ($20.02) is trading below our estimate of [[fair value]] ($25.26)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

EBOS.F Stock Overview

Engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. More details

EBOS.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	2/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 20.7% below our estimate of its fair value

Earnings are forecast to grow 6.8% per year

Earnings have grown 13.5% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Dividend of 3.31% is not well covered by free cash flows

My Notes

Capture your thoughts, links and company narrative

EBOS Group Limited Competitors

Patterson Companies

NasdaqGS:PDCO

US$2.7b

Henry Schein

NasdaqGS:HSIC

US$8.8b

Cardinal Health

NYSE:CAH

US$28.8b

Cencora

NYSE:COR

US$43.9b

Price History & Performance

Summary of share price highs, lows and changes for EBOS Group
Historical stock prices
Current Share Price	NZ$20.02
52 Week High	NZ$22.44
52 Week Low	NZ$20.02
Beta	0.25
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-4.73%

Recent updates

Shareholder Returns

	EBOS.F	US Healthcare	US Market
7D	0%	-0.4%	-1.1%
1Y	n/a	-10.3%	22.4%

Return vs Industry: Insufficient data to determine how EBOS.F performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how EBOS.F performed against the US Market.

Price Volatility

Is EBOS.F's price volatile compared to industry and market?
EBOS.F volatility
EBOS.F Average Weekly Movement	n/a
Healthcare Industry Average Movement	7.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: EBOS.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine EBOS.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1922	4,557	John Cullity	www.ebosgroup.com

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services.

EBOS Group Limited Fundamentals Summary

How do EBOS Group's earnings and revenue compare to its market cap?
EBOS.F fundamental statistics
Market cap	US$4.15b
Earnings (TTM)	US$168.93m
Revenue (TTM)	US$8.20b

24.6x

P/E Ratio

0.5x

P/S Ratio

Is EBOS.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EBOS.F income statement (TTM)
Revenue	AU$13.19b
Cost of Revenue	AU$11.56b
Gross Profit	AU$1.63b
Other Expenses	AU$1.36b
Earnings	AU$271.55m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.39
Gross Margin	12.38%
Net Profit Margin	2.06%
Debt/Equity Ratio	51.1%

How did EBOS.F perform over the long term?

See historical performance and comparison

Dividends

3.3%

Current Dividend Yield

78%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/31 00:45
End of Day Share Price	2024/12/19 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EBOS Group Limited is covered by 16 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Saul Hadassin	Barrenjoey Markets Pty Limited
Benjamin Brayshaw	Barrenjoey Markets Pty Limited
Lyanne Harrison	BofA Global Research